

Press Release

For immediate distribution

Glenmark partners with Pfizer to launch Abrocitinib in India

- *Abrocitinib is the first-of-its-kind oral advanced systemic treatment for adults with moderate-to-severe atopic dermatitis, to be made available in India.*
- *Abrocitinib provides rapid itch relief, sustained control of the disease and improved quality of life.*
- *Pfizer has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).*
- *Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS® and CIBINQO®, respectively.*

Mumbai, India, January 31, 2024: Pfizer and Glenmark Pharmaceuticals Ltd. (Glenmark) have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

When launched in India, it will be co-marketed under the brand names JABRYUS® and CIBINQO® by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate-to-severe AD, with improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the U.S., Japan, and China.

Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects^{1,2}. The persistent itching associated with moderate-to-severe AD disrupts daily life, impacting social interactions, work productivity, and overall well-being. Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, provides rapid itch relief, sustained disease control, and a vastly improved quality of life for patients³.

Meenakshi Nevatia, Country President and Managing Director of Pfizer India stated, "We believe in abrocitinib's transformative potential. Its approval is a milestone in bringing high-quality treatment for moderate-to-severe atopic dermatitis in India, enabling patients to manage symptoms more effectively. Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country."

Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals Ltd. said, "We are excited to collaborate with Pfizer India for the launch of abrocitinib in the country. The prevalence of atopic dermatitis in India has been reported to be increasing owing to changes in environmental factors with symptoms appearing during the initial years of life in around 80% of patients⁴. Being a leader in the dermatology therapy in India, this partnership will help us ensure availability of this effective treatment for the Indian patients suffering from moderate-to-severe AD; and further strengthen our position in the dermatology therapy space."

Prevalence of AD in India

The prevalence of AD has been on the rise over the past three decades with an estimated prevalence of AD of about 10-20% in developed countries³. Approximately 5.9%⁵ of adults in India are affected by AD, of which 4.4%⁶ suffer from a severe form of this disease. The symptoms of AD like itching and lack of sleep, lay a significant burden on the patients and their caretakers, affecting multiple aspects including their quality of life and mental health³.

---End---

1. Hanifin JM, Reed ML. A population-based survey of eczema in the United States. *Dermatitis*. 2007;18(2):82-91.
2. Bieber T. Atopic dermatitis. *Dermatology*. 2012;1(3):203-217.
3. Iznardo H, Roé E, Serra-Baldrich E, Puig L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. *Pharmaceutics*. 2023 Jan 23;15(2):385.
4. De A, Karekar S, Adhav C. Current Burden of Atopic Dermatitis in India: A Systematic Literature Review. *Indian Journal of Dermatology*. 2023 Jul 1;68(4):487-93.
5. Barnes M et al. Global Asthma Network Phase I, India: Results for allergic rhinitis and eczema in 127,309 children and adults. *Journal of Allergy and Clinical Immunology: Global*, Volume 1, Issue 2, 2022, Pages 51-60. 2. Kanwar AJ, De D. Epidemiology and clinical features of atopic dermatitis in India. *Indian J Dermatol*. 2011 Sep-Oct;56(5):471-5. doi: 10.4103/0019-5154.87112.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. The company has also been Great Place To Work® Certified™ in India for FY 2023. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

About Pfizer: Breakthroughs that Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with healthcare providers, governments, and local communities to support and expand access to reliable, and affordable healthcare around the world. For more than 170 years, we have worked to make a difference for all who rely on us. Please visit our website www.pfizer.co.in for more such updates.

Contact us at:

From Glenmark Pharmaceuticals Ltd.	From Pfizer
Udaykumar Murthy +91 9960377617 corpcomm@glenmarkpharma.com	Roma Nair +91 9987008170 roma.nair@pfizer.com

- Hanifin JM, Reed ML. A population-based survey of eczema in the United States. *Dermatitis*. 2007;18(2):82-91.
- Bieber T. Atopic dermatitis. *Dermatology*. 2012;1(3):203-217.
- Iznardo H, Roé E, Serra-Baldrich E, Puig L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. *Pharmaceutics*. 2023 Jan 23;15(2):385.
- De A, Karekar S, Adhav C. Current Burden of Atopic Dermatitis in India: A Systematic Literature Review. *Indian Journal of Dermatology*. 2023 Jul 1;68(4):487-93.
- Barnes M et al. Global Asthma Network Phase I, India: Results for allergic rhinitis and eczema in 127,309 children and adults. *Journal of Allergy and Clinical Immunology: Global*, Volume 1, Issue 2, 2022, Pages 51-60. 2. . Kanwar AJ, De D. Epidemiology and clinical features of atopic dermatitis in India. *Indian J Dermatol*. 2011 Sep-Oct;56(5):471-5. doi: 10.4103/0019-5154.87112.